<DOC>
	<DOCNO>NCT00902200</DOCNO>
	<brief_summary>Double-masked , randomize , multi-center , placebo-controlled parallel-comparison AR-12286 .</brief_summary>
	<brief_title>A Study AR-12286 Patient With Elevated Intraocular Pressure ( IOP )</brief_title>
	<detailed_description>Subjects randomize receive AR-12286 Ophthalmic Solution 0.05 % , 0.1 % , 0.25 % vehicle ( one eye ) , q.d . ( AM ) x 7 day , q.d . ( PM ) x 7 day , b.i.d . x 7 day . The first dose administer clinic . Ocular safety ocular hypotensive efficacy evaluate clinic throughout period .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<criteria>1 . 18 year age great . 2 . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) . Unmedicated ( postwashout , require ) IOP &gt; = 24 mm Hg one eye 08:00 hour , &gt; = 21 mm Hg 10:00 , 12:00 16:00 hour postwashout measurement ( Visit 1 ) . 3 . Corrected visual acuity eye +1.0 logMAR ( logarithm mininum angle resolution ) good ETDRS ( Early Treatment Diabetic Retinopathy Study ) eye ( equivalent 20/200 ) . 4 . Able willing give sign informed consent follow study instruction . Either eye 1 . Intraocular pressure &gt; 36 mm Hg 2 . Known hypersensitivity component formulation topical anesthetic , ( benzalkonium chloride , etc . ) 3 . Ocular trauma within past six month , ocular surgery laser treatment within past three month . 4 . History evidence ocular infection inflammation , herpes simplex keratitis , clinically significant blepharitis conjunctivitis baseline ( Visit 1 ) .. 5 . Contact lens wear within 30 minute instillation study medication . 6 . Ocular medication kind within 30 day Visit 2 , exception ) ocular hypotensive medication ( must wash accord provided schedule ) , b ) lid scrub ( may use prior , Visit 2 ) c ) lubricate drop dry eye ( may use throughout study ) , 7 . Clinically significant ocular disease ( e.g . corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication one month judge safe ( i.e. , cupdisc ratio &gt; 0.8 ) . 8 . Central corneal thickness great 600 micron . 9 . Any abnormality prevent reliable applanation tonometry . Study eye : 10 . Glaucoma : pseudoexfoliation pigment dispersion component , history angle closure . Note : Previous laser peripheral iridotomy acceptable . 11 . Previous glaucoma intraocular surgery laser procedure study eye ( ) . 12 . Refractive surgery study eye ( ) ( e.g. , radial keratotomy , PRK ( photorefractive keratectomy ) , LASIK ( LaserAssisted situ Keratomileusis ) , etc. ) . General/Systemic : 13 . Clinically significant abnormality laboratory test screen ( See Appendix 1 ) . 14 . Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , cardiovascular endocrine disorder ) might interfere study . 15 . Participation investigational study within past 30 day . 16 . Changes systemic medication study could substantial effect IOP within 30 day prior screen , anticipate study . 17 . Due status preclinical safety program , woman childbearing potential pregnant , nursing , plan pregnancy , use medically acceptable form birth control . An adult woman consider childbearing potential unless one year postmenopausal three month postsurgical sterilization . All female childbearing potential must negative urine pregnancy test result screen examination must intend become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Intraocular pressure</keyword>
</DOC>